The U.S. Food and Drug Administration announced November 30, 2022 that it is pulling emergency use authorization for the monoclonal antibody treatment bebtelovimab because “it is not expected to neutralize Omicron subvariants” the agency said in a statement.

The FDA recommends that health-care providers use other approved or authorized remedies for treating COVID-19. Current FDA approved or authorized products include the following: 

• Paxlovid 
• Veklury 
• Lagevrio 

For more information, please consult your healthcare provider and read the full statement from the FDA: FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region published November 30, 2022.